Clinical trial
Engineered Dendritic Cell Vaccines for Remission Maintenance in Multiple Myeloma Patients
NCT06435910 is registered in ClinicalTrials.gov with Shenzhen Geno-Immune Medical Institute as lead sponsor.
Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.
Registry record
As filed in ClinicalTrials.gov.
- Title
- Engineered Dendritic Cell Vaccines for Remission Maintenance in Multiple Myeloma Patients
- Lead sponsor
- Shenzhen Geno-Immune Medical Institute
- Phase
- Phase 1
- Overall status
- Not yet recruiting
- Start date
- June 30, 2027
- Completion date
- December 31, 2029
- Enrollment
- 10 (estimated)
- Sites
- 1
Conditions
As the registry lists them; a condition with its own page is linked.
multiple myeloma or plasmacytoma